Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of treatments that harness the power of the immune system to extend life. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Nearly 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.
Our Digital Meetings
Our March 5 Digital Meetings
- 9:10am-9:40am
- Meeting number: 133 402 3816
- Meeting password: Provenge
- 12:00pm-1:00pm
- Meeting number: 133 402 3816
- Meeting password: Provenge
- 3:00pm-3:20pm
- Meeting number: 133 011 4998
- Meeting password: Provenge
Our March 6 Digital Meetings
- 9:55am-10:15am
- Meeting number: 133 747 8205
- Meeting password: Provenge
- 12:00pm-1:00pm
- Meeting number: 133 767 9020
- Meeting password: Provenge
Product & Contact Information
Offered By
